Meflynate Xl

Methylphenidate hydrochloride, the active ingredient in Meflynate Xl, is a central nervous system stimulant presented as an oral formulation for oral use. It is prescribed to manage symptoms of attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH USA supplies Meflynate Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for regulated medicines. Our network ensures timely delivery across Europe, Asia, Africa and the Americas.

Methylphenidate hydrochloride is a central nervous system stimulant used in the management of neurodevelopmental and sleep‑wake disorders. - Attention deficit hyperactivity disorder (ADHD) in children and adolescents: improves concentration, reduces hyperactivity and impulsivity. - Attention deficit hyperactivity disorder (ADHD) in adults: enhances focus and executive function. - Narcolepsy: decreases daytime sleepiness and improves wakefulness.

Methylphenidate hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Appetite loss: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach upset: nausea, abdominal discomfort.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, tachycardia. - Psychiatric symptoms: new or worsening anxiety, agitation, psychosis. - Allergic reactions: rash, urticaria, anaphylaxis.

When prescribing methylphenidate hydrochloride, clinicians should consider several precautionary measures to ensure safe use. - Assess cardiovascular health: evaluate blood pressure and heart rate before initiation. - Monitor growth in children: track height and weight regularly. - Review psychiatric history: be cautious in patients with anxiety, bipolar disorder or psychosis. - Avoid use with MAO inhibitors: ensure a washout period of at least 14 days. - Educate about misuse: inform patients of abuse potential and proper storage. - Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Methylphenidate hydrochloride can interact with several medications, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis. - Tricyclic antidepressants: increased risk of cardiovascular side effects. - Antihypertensive agents: may reduce blood pressure control.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase serotonin levels, watch for serotonin syndrome. - CYP2D6 inhibitors (e.g., fluoxetine): can raise methylphenidate plasma concentrations. - Antacids: may alter absorption, monitor therapeutic response.